Technology innovation for infectious diseases in the developing world

Infectious Diseases of Poverty

Quentin Ruiz-Esparza¹  Anthony D So¹ 

[1] Program on Global Health and Technology Access, Sanford School of Public Policy and Duke Global Health Institute, Duke University, 302 Towerview Drive, CB# 90312, Durham, North Carolina, 27708, USA

关键词: Open innovation;    Open source;    Business model;    D;    R&;    D collaboration;    R&;    Public health;    Policy;    Access;    Technology;    Innovation;   

Others  :  805884
DOI  :  10.1186/2049-9957-1-2

 received in 2012-08-10, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low- and middle-income countries (LMICs). However, a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs. While the pharmaceutical industry views emerging economies as potential new markets, most of the world’s poorest bottom billion now reside in middle-income countries--a fact that has complicated tiered access arrangements. However, product development partnerships--particularly those involving academic institutions and small firms--find commercial opportunities in pursuing even neglected diseases; and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation. Such innovation will be shaped by 1) access to building blocks of knowledge; 2) strategic use of intellectual property and innovative financing to meet public health goals; 3) collaborative norms of open innovation; and 4) alternative business models, some with a double bottom line. Facing such resource constraints, LMICs are poised to develop a new, more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.

【 授权许可】

   
2012 So and Ruiz-Esparza; licensee BioMed Ltd.

【 参考文献 】

• [1]Lopez AD, Mathers CD, Ezzati M, et al.: Measuring the Global Burden ofDisease and Risk Factors, 1990–2001. In Global Burden of Disease and Risk Factors. Chapters 1 and 2. Washington, DC: The International Bank for Reconstruction and Development / The World Bank; 2006. http://www.dcp2.org/pubs/GBD/ webcite
• [2]World Health Organization: Mortality and Burden of Disease Estimates for WHO Member States in 2004. 2009.
• [3]United Nations: Millennium Development Goals Report 2011. United Nations: New York; 2011. http://www.un.org/millenniumgoals/11_MDG%20Report_EN.pdf webcite
• [4]MDG Targets and Indicators. http://www.un-ngls.org/spip.php?page=amdg10&id_article=2330 webcite
• [5]Global Health Technologies Coalition / Policy Cures: Saving Lives and Creating Impact: Why Investing in Global Health Research Works. 2012. http://policycures.org/downloads/Saving%20lives%20and%20creating%20impact.pdf webcite
• [6]World Bank: Health Expenditure per Capita, data from 1995 to 2010. 2010. http://data.worldbank.org/indicator/SH.XPD.PCAP webcite
• [7]Médecins Sans Frontières: Untangling the Web of Antiretroviral Price Reductions. 14th edition. Geneva, Switzerland: Médecins Sans Frontières; 2011.
• [8]World Health Organization, UNICEF, UNAIDS: Global HIV/AIDS Response. Geneva, Switzerland: Epidemic Update and Health Sector Progress towards Universal Access World Health Organization Department of HIV/AIDS; 2011. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf webcite
• [9]UNAIDS: AIDSInfo Database: Number of People Living with HIV, 1990 to 2009. 2009. http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/ webcite
• [10]World Bank: Health Expenditure per Captia, data from 1995 to 2010. 2010. http://data.worldbank.org/indicator/SH.XPD.PCAP webcite
• [11]Lu Y, Hernandez P, Abegunde D, Edejer T: The World Medicines Situation 2011: Medicine Expenditures. 3rd edition. Geneva, Switzerland: World Health Organization; 2011:7.
• [12]Adeyi O: Affordable Medicines Facility-malaria (AMFm): Achievements to date, UNITAID Consultative Forum. Geneva, Switzerland: UNITAID; 2011.
• [13]Health Action International: Retail prices of ACTs co-paid by the AMFm and other antimalarial medicines: report of price-tracking survey. Geneva, Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2011.
• [14]Expert Advisory Group on the Affordable Medicines Facility-malaria (AMFm): Review of the AMFm Phase 1 Independent Evaluation Preliminary Report. Geneva, Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2012.
• [15]Rutta E, Kibassa B, McKinnon B, Liana J, Mbwasi R, Mlaki W, Embrey M, Garba M, Shekalaghe E, Kimatta S, Hiiti S: Increasing Access to Subsidized Artemisinin-based Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania. Health Res Pol Syst 2011, 9:22. BioMed Central Full Text
• [16]The William Davidson Institute: Affordable Medicines Facility-malaria (AMFm): Assessment of the effects of the AMFm on market dynamics of API and ACTs at the global level. Ann Arbor, Michigan: William Davidson Institute, The University of Michigan; 2012. http://www.theglobalfund.org/en/amfm/discussionpapers/ webcite
• [17]Zhang J, Pritchard E, Hu X, Valentin T, Panilaitis B, Omenetto FG, Kaplan DL: Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci 2012, 109(30):11981-11986.
• [18]Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA: Ethical and Scientific Implications of the Globalization of Clinical Research. N Engl J Med 2009, 360(8):816-823.
• [19]World Health Organization: Mortality and Burden of Disease Estimates for WHO Member States in 2004. 2009.
• [20]World Health Organization: Mortality and Burden of Disease Estimates for WHO Member States in 2004. 2009.
• [21]Policy C: Global Funding for Innovation for Neglected Diseases (G-FINDER). 2011. http://g-finder.policycures.org/gfinder_report/ webcite
• [22]Sumner A: The New Bottom Billion: What If Most of the World’s Poor Live in Middle-Income Countries?. Washington, DC: Center for Global Development; 2011. http://www.cgdev.org/files/1424922_file_Sumner_brief_MIC_poor_FINAL.pdf webcite
• [23]Nwaka S, Ilunga TB, Da Silva JS, Rial Verde E, Hackley D, De Vré R, Mboya-Okeyo T, Ridley RG: Developing ANDI: A Novel Approach to Health Product R&D in Africa. PLoS Med 2010, 7(6):e1000293. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000293#pmed-1000293-g001 webcite
• [24]Moran M: A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need. PLoS Med 2005, 2(9):e302. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020302 webcite
• [25]Ponder E, Moree M: Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape. Washington, DC: BIO Ventures for Global Health; 2012.
• [26]Associated Press: Innovative drug approvals up sharply in 2011, gov’t increasingly funds infectious disease R&D. Washington, DC: Washington Post; 2012.
• [27]Global Health Strategies Initiatives: Shifting Paradigm: How the BRICS are Reshaping Global Health and Development. New York, NY: Global Health Strategies Initiatives; 2012.
• [28]Institute for Applied Economic Research: Brazilian Cooperation for International Development: 2005–2009. Rio de Janeiro, Brazil: Institute for Applied Economic Research; 2011.
• [29]GAVI Alliance. Brazil: Donor Profiles; http://www.gavialliance.org/funding/donor-profiles/brazil/ webcite
• [30]UNITAID: UNITAID Annual Report 2011: Five Years for Better Health. Geneva, Switzerland: UNITAID; 2011.
• [31]Technology transfer and establishment of an antiretroviral drugs factory in Mozambique. http://www.fiotec.fiocruz.br/institucional/index.php?option=com_content&view=article&id=805:technology-transfer-and-establishment-of-an-antiretroviral-drugs-factory-in-mozambique&catid=126&Itemid=489&lang=en webcite
• [32]AFP: Mozambique launches Brazil-funded drugs plant to battle HIV. Yahoo! News. 2012. http://news.yahoo.com/mozambique-launches-brazil-funded-drugs-plant-battle-hiv-174318951.html webcite
• [33]Drugs for Neglected Diseases Initiative: A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria. Geneva, Switzlerand: Drugs for Neglected Diseases Initiative; 2008. http://dndi.org/press-releases/2008/113-a-worldwide-public-partnership-makes-available-a-new-once-a-day-fixed-dose-combination-against-malaria.html webcite
• [34]Lu Y, Hernandez P, Abegunde D, Edejer T: The World Medicines Situation 2011: Medicine Expenditures. 3rd edition. Geneva, Switzerland: World Health Organization; 2011.
• [35]Commission on Intellectual Property Rights: Innovation and Public Health: Public Health, Innovation and Intellectual Property Rights. Geneva, Switzerland: World Health Organization; 2006. http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf webcite
• [36]Sixty-First World Health Assembly: Global strategy and plan of action on public health, innovation and intellectual property,” WHA61.21, Agenda item 11.6. 2008. http://apps.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf webcite
• [37]Consultative Expert Working Group on Research and Development: Financing and Coordination: Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination. Geneva, Switzerland: World Health Organization; 2012. http://www.who.int/phi/CEWG_Report_5_April_2012.pdf webcite
• [38]WHO: Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits. Geneva, Switzerland: World Health Organization; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241503082_eng.pdf webcite
• [39]Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W: An international technology platform for influenza vaccines. Vaccine 2011, 29(Supplement 1):A8-A11. Available at: http://www.sciencedirect.com/science/article/pii/S0264410X11006906 webcite
• [40]So AD, Stewart E: Sharing Knowledge for Global Health. In The U.S. Commitment to Global Health: Recommendations for the Public and Private Sectors. Washington, DC: Appendix F. U.S. Institute of Medicine Committee on the U.S. Commitment to Global Health; 2008. [ http://www.ncbi.nlm.nih.gov/books/NBK23792/ webcite]
• [41]ChEMBL-Neglected Tropical Disease archive: ChEMBL-Neglected Tropical Disease archive. [ https://www.ebi.ac.uk/chemblntd/ webcite]
• [42]Medicines Patent Pool: FAQ on the Pool/Gilead Licenses: October 2011--Frequently Asked Questions on the Implications of the Gilead/Medicines Patent Pool License. [ http://www.medicinespatentpool.org/licensing/current-licences/the-medicines-patent-poolgilead-licences-questions-and-answers/faq-on-the-poolgilead-licences/ webcite]
• [43]Collins F: Reengineering translational science: the time is right. Sci Transl Med 2011, 3(90:90cm17):1-6. [ http://www.nih.gov/about/director/articles/translational_science_07062011.pdf webcite]
• [44]Mimura C, Cheng J, Penhoet B: Perspective: Socially Responsible Licensing, Euclidean Innovation, and the Valley of Death. 2011. [Stanford Journal of Law, Science and Policy] UC Berkeley Public Law Research Paper No. 1928837. [ http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1928837 webcite]
• [45]Marshall E: Bermuda Rules: community spirit, with teeth. Science 2001, 291:1192.
• [46]U.S. National Institutes of Health: Final NIH Statement on Sharing Research Data, 2003. Bethesda, MD: Notice NOT-OD-03-032. U.S. National Institutes of Health; 2003. [ http://grants.nih.gov/grants/guide/notice-files/not-od-03-032.html webcite]
• [47]U.S. National Institutes of Health: Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice. 1999. [Federal Register Notice] [ http://www.ott.nih.gov/policy/rt_guide_final.html webcite]
• [48]Chesbrough HW: The Era of Open Innovation. 2011, 35-41. [Top 10 Lessons on the New Business of Innovation. MIT Sloan Management Review] (originally published Spring 2003). [ http://scholar.google.com/scholar_url?hl=en&q=http://sloanreview.mit.edu/files/2011/06/INS0111-Top-Ten-Innovation.pdf%23page%3D37&sa=X&scisig=AAGBfm1PbObbGnXtYKHIQDvZFi1_CRc2Dg&oi=scholarr webcite]
• [49]Council for Scientific and Industrial Research: Frequently Asked Questions, Open Source Drug Discovery Initiative. [ http://www.osdd.net/faq-s webcite]
• [50]Jadhav SS, Gautam M, Gairola S: Emerging markets & emerging needs: Developing countries vaccine manufacturers’ perspective & its current status. Biologicals 2009, 37:165-168.
• [51]Waning B, Diedrichsen E, Moon S: A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 2010, 13:35. [ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944814/ webcite] BioMed Central Full Text
• [52]Radjou N, Prabhu J, Ahuja S: Jugaad Innovation: Think Frugal, Be Flexible, Generate Breakthrough Growth. San Francisco, CA: Jossey-Bass; 2012.
• [53]Bound K, Thornton I: Our Frugal Future: Lessons from India’s Innovation System. London, United Kingdom: Nesta; 2012. [ http://www.nesta.org.uk/library/documents/OurFrugFuture.pdf webcite]
• [54]So AD, Ruiz-Esparza Q, Gupta N, Cars O: 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. Br Med J 2012, 344:e1782.
• [55]INSEAD, World Intellectual Property Organization: The Global Innovation Index 2012: Stronger Innovation Linkages for Global Growth. Fontainebleau, France: INSEAD and World Intellectual Property Organization; 2012. Edited by Dutta S
• [56]Malhotra A, Kleiner A, Geller LW: A Gandhian Approach to R&D. 2010. [Strategy + Business] [ http://www.strategy-business.com/article/10310?pg=all webcite]
• [57]Prahalad C, Mashelkar R: Innovation’s Holy Grail. Harvard Business Review 2010, 88(7/8):132-141. [serial online]
• [58]Clayton Christensen: Key concepts--disruptive innovation. [ http://www.claytonchristensen.com/key-concepts/ webcite]